Personalis Price to Free Cash Flow Ratio 2018-2024 | PSNL
Historical price to free cash flow ratio values for Personalis (PSNL) since 2018.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Personalis Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2025-01-23 |
6.15 |
|
0.00 |
| 2024-09-30 |
5.38 |
$-0.98 |
0.00 |
| 2024-06-30 |
1.17 |
$-1.30 |
0.00 |
| 2024-03-31 |
1.49 |
$-1.38 |
0.00 |
| 2023-12-31 |
2.10 |
$-1.39 |
0.00 |
| 2023-09-30 |
1.21 |
$-1.62 |
0.00 |
| 2023-06-30 |
1.88 |
$-2.05 |
0.00 |
| 2023-03-31 |
2.76 |
$-2.60 |
0.00 |
| 2022-12-31 |
1.98 |
$-2.63 |
0.00 |
| 2022-09-30 |
2.97 |
$-2.49 |
0.00 |
| 2022-06-30 |
3.45 |
$-2.17 |
0.00 |
| 2022-03-31 |
8.19 |
$-2.02 |
0.00 |
| 2021-12-31 |
14.27 |
$-1.87 |
0.00 |
| 2021-09-30 |
19.24 |
$-1.55 |
0.00 |
| 2021-06-30 |
25.30 |
$-1.51 |
0.00 |
| 2021-03-31 |
24.61 |
$-1.35 |
0.00 |
| 2020-12-31 |
36.61 |
$-1.34 |
0.00 |
| 2020-09-30 |
21.67 |
$-1.80 |
0.00 |
| 2020-06-30 |
12.97 |
$-0.18 |
0.00 |
| 2020-03-31 |
8.07 |
$-1.75 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.396B |
$0.073B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
